Company presentation

BioGaia in short

2

555 patents in 30 families

Listed on Nasdaq Stockholm (mid cap list)

Products in more than 100 markets

Offices in Sweden (Stockholm, Lund, Eslöv, Gothenburg), Singapore, USA, Japan, South Africa

160 employees

Founded in 1990

555

Three subsidiaries (BioGaia Production, BioGaia Pharma, MetaboGen)

To be the ground-breaking leader in probiotics that contributes to improved health by educating people and

providing probiotic products for defined indications

OUR MISSION

4

30 years of probiotic innovation

Founded by Peter

Rothschild and Jan Annwall

Listed on Nasdaq

Stockholm

BioGaialaunches

world’s first probiotic chewable

tabletAgreement with

Ascendis (South Africa)

BioGaia Production is formed

Agreement with Nóos

(Italy)

BioGaia launches

world’s first probiotic

dropsAgreement

with Verman(Finland)

Agreement with

EwopharmaAG (Eastern

Europe)Agreement with Ferring

(Middle East)

BioGaiaJapan

founded

First agreement with Nestlé

Agreement with Abbott (LatAm &

Asia)BioGaia

invests in MetaboGen

1998 2002 20061990 2000 2003 20082004 2014 2017

BioGaiasets up

subsidiary BioGaiaPharma

2018

BioGaia sets up The

Foundation to Prevent Antibiotic

Resistance

5

BioGaia has a unique business model

Flexible business model

NETWORKResearchers

Preclinical and clinicalstudies at hospitals

and universities

BioGaiaProduct development

Product strategiesResearch

Quality assurance systemMarketing support

IP

NETWORKSuppliers

Production andpackaging

NETWORKPartners

Pharmaceutical orhealthcare companies

with sales organizations

BioGaia

Universities and hospitals where research is conducted

Manufacturing andpackaging units

Partners with salesof products

BioGaia business model

• Developing products sold around the world via a network of distribution partners

• Building a strong brand towards healthcare professionals and consumers

7

8

• More than 70 countries

• >70% of sales of finished consumer products*

• Build value, less dependence on patents

BioGaia brand

* BioGaia brand incl co-branding

224

18,000

…clinical studies. Results published in scientific journals

All BioGaia probiotics areclinically proven

* Previously known as Lactobacillus

…individuals of all ages have taken part in clinical studies

with BioGaia’s human strains of Limosilactobacillus* reuteri

10

BioGaia focus areas

11

Stay HealthyMother & Child

12

Mother & Child

INFANCYColic,

Infection Protection

BIRTHAASE*, C-section, Infection Protection

PREGNANCYInfection Protection,

AASE*, Constipation, Gingivitis

*Antibiotic associated side-effects**Functional Abdominal Pain

BioGaia focuses on prevention and treatment during pregnancy, in infancy and throughout childhood.

CHILDHOODFAP**, AASE*,

Constipation, Acute Gastroenteritis

13

Mother & ChildBIRTH

AASE*, C-section, Infection Protection

*Antibiotic associated side-effects**Functional Abdominal Pain

BioGaia focuses on prevention and treatment during pregnancy, in infancy and throughout childhood.

INFECTION PROTECTION

Strengthen immune system

BONE HEALTHBone loss

(osteopenia)

ORAL HEALTHPeriodontal disease

GUT HEALTHGut motility

Gut inflammation

BioGaia focuses on prevention of age-related conditions and maintenance of general well-being

Stay Healthy

BioGaia focuses on prevention of age-related conditions and maintenance of general well-being

Stay Healthy

16

Sustainability a part of BioGaia’s DNA

Sustainability framework

Sustainable packaging

Sustainable raw materials

Transparent and robust science

Product quality and safety

Responsible partners

Responsible suppliers

Responsible research

The Foundation to Prevent Antibiotic Resistance

Children's MissionFriends of PanziClimate Offset

Healthy networks

Health & wellbeing

Training & development

Safety in production

Healthy workplace Healthy business Healthy products

Investments for global health

Business ethics

Climate change

Environmental impact in production

Intellectual property

18

The global probiotics market

Increasing out-of-pocket healthcare expenditure

19

0

200

400

600

800

1000

1200

1970

1972

1974

1976

1978

1980

1982

1984

1986

1988

1990

1992

1994

1996

1998

2000

2002

2004

2006

2008

2010

2012

2014

2016

2018

USD

AUS

FRA

IND

JPN

MEX

SWE

USA

Source: OECD 2019

20Source: Euromonitor 2019

0

1 000

2 000

3 000

4 000

5 000

6 000

7 000

8 000

9 000

10 000

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019202

0F202

1F202

2F202

3F202

4F

Mar

ket v

alue

(USD

m)

4.3%

5.7%

Global probiotic market estimated to grow by CAGR 4-5%

11.4%

8.7%

• Growing interest in health

• Sustainable companies are winners

• Antibiotic resistance is a growing threat

• High growth opportunities in APAC region

• Increased access through growing online channel and e-commerce players

Market trends point towards probiotics

21

BioGaia Group – The Microbiome Partner

BioGaia Group organisation

22(Number of employees)

BioGaia Production and Centre of Excellence

• Production of BioGaia drops, easydropper, minipack and samples

• GMP pharma certified

• Centre of Excellence – D&R and Product development • Small-scale trials and small-scale production• Test and analyse raw material and finished products• Discover and develop understanding of current and new bacterial strains

23

Development of next generation probiotics

• Develop products from novel anaerobic strains, derived from the human gut but not previously used as probiotics, targeted for precise indications

• Food supplements or drugs• Evaluating potential probiotic strains by

metagenomic technologies and metabolic modelling

• In-house development of unique technology for production of products with anaerobic strains

• Strain development, small-scale production and clinical study preparation performed in highly specialised facilities outside Gothenburg

• First product in clinical phase

Pipeline

Metabolic disease (NAFLD, prediabetes)• Two-strain combination• Safety study completed• Efficacy study to be performed 2021

Intrahepatic Cholestasis in Pregnancy (ICP)• Exploratory study completed• In partnership with Ferring Pharmaceuticals

Immunotherapy in melanoma• Prospective study ongoing• Goal: companion product to improve response to treatment with current drugs